About this Journal Submit a Manuscript Table of Contents
Evidence-Based Complementary and Alternative Medicine
Volume 2012 (2012), Article ID 414536, 10 pages
Research Article

Therapeutic Effect of Yi-Chi-Tsung-Ming-Tang on Amyloid β1−40-Induced Alzheimer's Disease-Like Phenotype via an Increase of Acetylcholine and Decrease of Amyloid β

1Department of Neurology, Show Chwan Memorial Hospital, Changhua, Taiwan
2Graduate Institute of Life Sciences, National Chung Hsing University, Taichung 40001, Taiwan
3Department of Nursing, College of Medicine & Nursing, HungKuang University (HKU), Taichung 40001, Taiwan
4School of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, College of Pharmacy, China Medical University, Taichung 40001, Taiwan
5School of Health, National Taichung University of Science and Technology, Taichung 40401, Taiwan
6Department of Veterinary Medicine, National Chung Hsing University, Taichung 40001, Taiwan
7Graduate Institute of Biomedical Sciences, National Chung Hsing University, Taichung 40001, Taiwan

Received 13 March 2012; Accepted 23 April 2012

Academic Editor: Paul Siu-Po Ip

Copyright © 2012 Chung-Hsin Yeh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Alzheimer's disease (AD) is an irreversible neurodegenerative disorder characterized by amyloid accumulation, neuronal death, and cognitive impairments. Yi-Chi-Tsung-Ming-Tang (YCTMT) is a traditional Chinese medicine and has never been used to enhance cognitive function and treat neurodegenerative disorders such as senile dementia. Whether YCTMT has a beneficial role in improving learning and memory in AD patients remains unclear. The present study showed that oral administration of YCTMT ameliorated amyloid-β- (Aβ1−40) injection-induced learning and memory impairments in rats, examined using passive avoidance and Morris water-maze tests. Immunostaining and Western Blot results showed that continuous Aβ1−40 infusion caused amyloid accumulation and decreased acetylcholine level in hippocampus. Oral administration of medium and high dose of YCTMT 7 days after the Aβ1−40 infusion decreased amyloid accumulation area and reversed acetylcholine decline in the Aβ1−40-injected hippocampus, suggesting that YCTMT might inhibit Aβ plague accumulation and rescue reduced acetylcholine expression. This study has provided evidence on the beneficial role of YCTMT in ameliorating amyloid-induced AD-like symptom, indicating that YCTMT may offer an alternative strategy for treating AD.

1. Introduction

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that gradually impairs memory and cognition [1]. It has been estimated that about 5% of the population older than 65 years is affected by AD [2]. The incidence of AD doubles every 5 years and 1275 new cases diagnosed yearly per 100,000 persons older than 65 [3]. In 2010, the number of worldwide AD patients has reached 35 million [4, 5]. The high cost spending on AD treatment and patient care makes AD become one of the most challenging brain disorders in elder human and causes tremendous financial burden.

AD is characterized by cognitive impairment, memory loss, dementia in neuropsychology, and intracellular neurofibrillary tangles and senile plaques in histopathology [6, 7]. During the progress of AD, short-term memory is first affected due to neuronal dysfunction and degeneration in the hippocampus and amygdala. The pathogenic mechanisms of AD include impaired cholinergic function, increased oxidative stress, induction of the amyloid cascade (i.e., amyloid beta, Aβ, deposition, and plaque formation), expression of inflammatory mediators, deficiencies in steroid hormones, and appearance of glutamate-mediated excitotoxicity [2]. The amyloid cascade hypothesis, which suggests a pivotal role for Aβ in the pathogenesis of AD, is accepted by most investigators in this field [8]. Aβ is the major component of the senile plaques [911], and extensive studies have indicated that Aβ peptides contribute to the neuronal cell loss and pathogenesis of AD [12, 13].

Aβ1−40 is a prone-to-aggregation product of amyloid precursor protein (APP) proteolytic cleavage [14, 15] and has been shown to have a toxic effect on endothelial cells in cerebral circulation in vitro [16]. Direct injection of synthetic Aβ1−40 into particular brain regions has been used to induce AD-like pathological changes in animal model [17]. Recently, Passos and colleagues described a mouse model of acute inflammation induced by Aβ1−40 intracerebroventricular injection that appears to mimic the early phase of AD progression [18, 19]. Increased oxidative stress owning to lipid peroxidation, protein oxidation, and hydrogen peroxide formation may also be involved in Aβ-induced neurotoxicity [20]. Indeed, antioxidant therapy prevents the learning and memory deficits induced by Aβ in rats [21], and it also delays the clinical progression of the disease in humans [22]. Proteomic analysis using peptide mass fingerprint (PMF) has also revealed Aβ1−40-induced changes in protein expression in the rat hippocampus [23].

Acetylcholine (Ach), a neurotransmitter of cholinergic system, influences neuron plasticity and plays an important role in cognition and memory [24, 25]. Aβ deposition is closely associated with dysfunction and degeneration of cholinergic neuronal circuits in the basal forebrain nuclei and also results in deficit of Ach in cortical and hippocampal areas [26]. Consistently, upregulation of acetylcholinesterase, an enzyme that catalyzes the hydrolysis of Ach, has been reported within and around amyloid plaques [27], and upregulation of its activity has also been shown to encourage the assembly of Aβ into fibrils that lead to Aβ toxicity [28]. The level of Ach has also been shown to be related to the degree of amnesia and Aβ depositions in the AD brain [29]. All these studies suggest that Ach plays an important role in AD [30, 31].

While up to now there has been no effective treatment for AD, targeting Aβ production and reversing Ach diminution are attractive therapeutic strategies for AD [32, 33]. In addition, alternative medicines that improve AD symptom have also been recently identified and they are natural and may be safer and more effective than currently commercialized drugs for AD [32, 33]. YCTMT was first introduced by an ancient Chinese physician, Dong-Yuan Li, in Jin Dynasty (AD 1200s). YCTMT is a decoction made of various Chinese herbs including Astragali radix, Ginseng radix, Puerariae radix, Paeoniae lactiforae, Phellodendri contex, Viticis fructus, Cimicifugae uralensis, and Glycyrrhiza uralensis. Ginseng can reduce oxidative stress that damages neuroplasticity, neurogenesis, and memory formation [34, 35]. In addition, Ginseng has also been shown to promote axonal and dendritic extension [36]. Astragalus promotes axonal maturation and prevents memory loss in mice [37]. Puerarin and Glycyrrhiza have been shown to have neuroprotective effects against Aβ treatment in mouse model [38, 39]. According to the theory of Dr. Li, Yi-Chi-Tsung-Ming-Tang (YCTMT, also known as Yiqicongming decoction) treats or prevents dizziness, tinnitus, and blurred vision. Therefore, it is intriguing to know whether YCTMT also has a beneficial effect on ameliorating AD-related symptoms. The aim of this study was to evaluate the effect of YCTMT treatment on Aβ1−40-induced AD-like symptoms and possible underlying mechanism.

2. Materials and Methods

2.1. Drugs and Reagents

YCTMT is composed of Astragali radix, Ginseng radix, Puerariae radix, Paeoniae lactiforae, Phellodendri contex, Viticis fructus, Cimicifugae uralensis, and Glycyrrhiza uralensis in a ratio of 5 : 5 : 5 : 1 : 1 : 1.5 : 3 : 5 (dry weight). All components were purchased from a Chinese herbal shop in Taichung city, Taiwan, and confirmed by Professor Ming-Tsuen Hsieh. YCTMT (0.5 kg) was prepared as a mixture of all above components and extracted with 5 L distilled water at 100°C. The liquid extract was powdered by heating in a rotary vacuum evaporator. In the study, YCTMT powder was dissolved in distilled water to make the final concentrations at 0.5, 1.0, and 2.0 g/mL. Aβ1−40 was purchased from Tocris Bioscience (Ellisville, MO, USA) and dissolved in a vehicle containing 35% acetonitrile and 0.1% trifluoroacetic acid. Other chemicals were purchased from Sigma-Aldrich (St Louis, MO, USA).

2.2. Animals

Adult male Sprague-Dawley (S.D.) rats (200–250 g) were purchased from BioLASCO (Taipei, Taiwan). The rats were maintained on a standard diet with water ad libitum and housed under a 12 : 12 light-dark cycle in a temperature-controlled environment ( 2 3 ± 1 °C). The animals were cared in accordance with guidelines provided by the Institutional Animal Ethics Committee of China Medical University (Taichung, Taiwan).

2.3. Rat Model with AD-Like Phenotype

Rat model with AD-like phenotype was developed by infusing Aβ1−40 into cerebral ventricle in the brain as described previously [18, 19, 40]. Briefly, one week before experiment, animals were randomly divided into five groups ( 𝑛 = 9 for each group). At day 0, rats were anaesthetized with phenobarbital (45 mg/kg, i.p.), placed in a Narishige stereotaxic instrument with the head being fixed. The skull was opened carefully, and a cannula was implanted into the right ventricle at coordinates: A 1 . 4 , L ± 2 . 4 , and V 7.2, using an atlas [41]. At day 1, vehicle or Aβ1−40 was continuously administered (25 pM/day) intraventricularly at an infusion rate of 0.5 μL/h for three weeks via the cannula that was powered by a miniosmotic pump (model 2002, Alzet, CA, USA). The control rats were infused with the vehicle only. From the 8th day, rats were fed with YCTMT (0.5, 1.0, and 2.0 g/kg/day) orally once a day. The experimental scheme was presented in Figure 1.

Figure 1: Experimental scheme.
2.4. Passive Avoidance Test

The passive avoidance test was performed at day 15 and 16 after surgery according to step-through passive avoidance task previously described [42]. Briefly, the guillotine door connecting the light and dark space was closed during the trial training. When a rat was placed in the light space, with its back facing the guillotine door, the door was opened. The time of step-through latency (STL) taken by the rat to enter the light space was measured with a stopwatch. Once the rat entered the dark space, the door was closed. An inescapable scrambled foot-shock (1.0 mA for 2 s) was then delivered through the grid floor. The rat was removed from the dark space 5 seconds after the shock was administered. Then, the rat was put back into the home cage until the retention trial was over.

2.5. Morris Water-Maze Test

A Morris water-maze test was used in the study to assess the memory capability [43, 44]. In brief, the apparatus consisted of a circular water tank (180 cm in diameter, 60 cm in height, filled with water in a depth of 50 cm, at 2 8 ± 1 °C) with a platform (11 cm in diameter) set under the water. Morris water-maze is a swimming-based model in which animals must learn to escape from water and step onto the platform. An escape platform was placed in a constant position in the center of one of the four quadrants of the tank and 1 cm below the water surface. For reference memory test, the rats were trained for 3 days (starting from day 17 to 19), 120 s per trial, and 4 trials per day starting at four different positions with 30 min intervals (Figure 1). If the rats could not find the hidden platform within each training session (120 s), the animals were led to it. If the rats swam onto the platform within 120 s, the rat was allowed to stay on the platform for 30 s then returned to home cage. In each training session, the latency to escape onto the hidden platform was recorded. For probe memory test, the hidden platform was removed on day 20, and memory retrieval was examined by a probe trail that lasted for 120 s in the pool. The time at which the animals crossed the annulus where the platform had been located was assigned. Twenty-four hours after probe trial, working memory (reacquisition) test was performed by measuring the time each rat spent in the new quadrant of the target platform.

2.6. Immunohistochemical Detection for A 𝛽 and Ach Expression in Brain

Rats were sacrificed at day 21 with pentobarbital (90 mg/kg, i.p.) and perfused transcardially with saline, followed by 4% paraformaldehyde in saline. After postfixation, the whole brain was removed and prepared for paraffin slice. Brain sections with 5 μm thickness were obtained on a microtome (Leica 2030 Biocut) at 1-mm interval from the stereotaxic coordinates between −1.46 mm and −3.40 mm Bregma. Brain sections were deparaffinized in xylene, rehydrated in a series of ethanol, and endogenous peroxidase quenched with 1% (v/v) H2O2 in methanol and microwaved for 15 min (with 650 W) in 0.01 M citrate buffer (pH 6.0). Nonspecific binding sites were blocked by blocking buffer containing 10% (v/v) goat normal serum and 0.1% Triton X-100 in PBS for 60 min at room temperature. Antibodies against Aβ (1 : 300 dilution, Convance, no. SIG-39220) and Ach (1 : 300 dilution, Chemicon, Billerica, MA, USA) were applied to sections overnight at 4°C. Sections were washed with PBS, incubated with biotinylated secondary antibody for 2 hr at 25°C, washed, and placed in avidin-peroxidase conjugate solution for 1 hr. The horseradish peroxidase reaction was detected with 0.05% diaminobenzidine and 0.03% H2O2. The reaction was stopped with H2O, and sections were dehydrated in an ethanol series, cleared in xylene, and coverslipped in permanent mounting solution. Protein expression area in each brain section was measured according to Lim et al. [45] and Liao et al. [46] with slight modification. Briefly, a full brain middle section area was measured by an image analyzer (Leica, Q500MC, Nussloch, Germany). Brain sections of each rat group were measured under 40x magnification, and at least 20 fields from each brain section were counted. The permillage of Aβ- or Ach-positive areas was calculated using the following equation: ‰ of Aβ or Ach area = (sum of Aβ- or Ach-positive area/total area of brain section) ×1000‰.

2.7. Western Blot

Protein extraction was performed in RIPA lysis Buffer 50 mM Tris, pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, protease inhibitor cocktail (sodium orthovanadate, sodium fluoride, EDTA, leupeptin), and 1 mM PMSF. Quantification of protein was performed using the BCA Protein Assay Kit (Beyotime). Equal amounts of protein samples were separated on 12% SDS-PAGE gels and transferred onto a PVDF membrane at 0.8 mA/cm2 for 1.5 h. The membrane was blocked with 5% nonfat milk in a 20 mM Tris-HCl (pH 7.4) containing 150 mM NaCl and 0.05% Tween20 (TBS-T) for 1 h at RT and incubated with the primary antibodies: β-amyloid antibody (1 : 1000 dilution, Abcam, Cambridge, MA, USA), antiacetylcholine (Chemicon, no. MAB5302.), and β-actin (abs, no. abs-24) at 4°C overnight. After being washed with TBS-T, the membrane was incubated with HRP-conjugated IgG (MILLIPORE, Chemiluminescent HRP Substrate, no. WBKLS0500) for 1 h at RT, washed with TBS-T again, and detected by ECL (Thermo Scientific). Densitometric quantitation was analyzed with FUJIFILM, Multi Gauge V3.0 Software, and standardized with β-actin. All Western Blotting samples were run in triplicate.

2.8. Statistical Analysis

All of the data obtained were expressed as m e a n ± s t a n d a r d errors of means (SEM) and analyzed using one-way analysis of variance (ANOVA), followed by post hoc between-group analyses using Scheffé’s test for multigroup comparisons. The criterion for statistical significance was 𝑃 < 0 . 0 5 in all evaluation.

3. Results

3.1. YCTMT Posttreatment Reversed Aβ1−40-Mediated Impairment in Memory Retention

Result from passive avoidance test showed that at day 15 after Aβ1−40 infusion significantly reduced the step through latency (STL) of treated mice compared to the vehicle injection ( 𝑃 < 0 . 0 5 , Figure 2), suggesting an Aβ1−40-induced impairment in memory retention after 2-week continuous injection. YCTMT posttreatment for 7 days with doses of 1.0 and 2.0 g/kg/day, but not 0.5 g/kg/day, significantly attenuated Aβ1−40-mediated reduction in STL ( 𝑃 < 0 . 0 5 , Figure 2), indicating that YCTMT reversed Aβ1−40-mediated impairment in a dose-dependent manner. There was no significant difference between the control and YCTMT-treated groups at 1.0 and 2.0 g/kg/day. This result suggested that treatment with YCTMT recovered Aβ1−40-induced deficit in memory retention in rats.

Figure 2: Passive avoidance test at day 15 after Aβ1−40 infusion. Aβ1−40 infusion reduced step-through latency of rats, and it was restored by YCTMT posttreatment ( 𝑛 = 9 for each group). YCTMT (0.5, 1.0, and 2.0 g/kg/day) was administrated for a week before test. *Represents significant difference between the indicated and normal control group; #between the indicated and Aβ1−40 group, 𝑃 < 0 . 0 5 .
3.2. YCTMT Effectively Reversed Aβ1−40-Induced Impairments in Learning and Memory

To further evaluate the therapeutic effect of YCTMT on Aβ1−40-induced impairments in learning and memory, Morris water maze test was conducted. In reference memory test, these Aβ1−40-treated animals showed significantly longer escape latency than normal control animals at day 17, 18, and 19 postinfusion of amyloid (Figure 3(a)). Posttreatment of YCTMT with the lowest dose of 0.5 g/kg/day showed no effect on Aβ1−40-caused deficits. However, YCTMT treatment at dose of 1.0 g/kg/day significantly reduced escape latency in Aβ1−40-treated rats at day 17 and 19, but not at day 18. Posttreatment with 2.0 g/kg/day YCTMT reversed increased escape latency caused by Aβ1−40 injection at all three test days (day 17 to 19), and the latency reached the level as short as that of normal control. These results indicated that Aβ1−40-induced impairments in spatial learning memory were reversed by posttreatment with YCTMT in a dose-dependent manner.

Figure 3: YCTMT posttreatment improved memory of Aβ1−40-infused rat in Morris water-maze test. (a) Reference memory test at day 17–19. (b) Probe test at day 20. (c) Working memory test at day 21. Aβ1−40-infused rats were administrated with YCTMT (0.5, 1.0, and 2.0 g/kg/day) before tests. *Represents significant difference between the sham and Aβ1−40 on the same day; #is for the comparison between Aβ1−40 and Aβ1−40 + YCTMT on the same day, 𝑃 < 0 . 0 5 .

The beneficial effect of YCTMT on Aβ1−40-induced learning deficit was further analyzed using probe and working memory tests. The number of annulus crossing, referred to the number of passing over the previous platform site, was measured at day 20. Result showed that number of annulus crossings in Aβ1−40-treated group was significantly lower than that of control group, whereas YCTMT posttreatment significantly elevated the number in a dose-dependent manner and showed significance at 1.0 and 2.0 g/kg/day ( 𝑃 < 0 . 0 5 , Figure 3(b)). Compared to the control group, Aβ1−40-treated group also showed significantly longer escape latency to found the platform at a constant location and to find the hidden platform at a new location during the reference memory test (day 17–19, Figure 3(a)) and during the working memory test (day 21, Figure 3(c)), respectively, suggesting the Aβ1−40-induced impairments in reference and working memory in injected rats. Posttreatment with YCTMT at dose of 1.0 and 2.0 g/kg/day significantly reversed Aβ1−40-caused increase of escape latency. These results again demonstrated that YCTMT was able to ameliorate Aβ1−40-caused impairment in learning and memory in a variety of forms.

3.3. YCTMT Significantly Decreased Aβ1−40-Induced Aβ Plaque Area

To investigate the effect of YCTMT posttreatment on amyloid protein burden in the brain, sections were analyzed with immunohistochemical staining. 4G8 antibody against amino acid residues 17–24 of beta-amyloid was used in the study (Figures 4(a)4(e)). Intracerebroventricular (i.c.v.) administration of Aβ1−40 significantly increased Aβ plaque area (arrow in Figure 4(b)) in hippocampus compared with vehicle injection in the control group (Figure 4(a)). Amyloid accumulation was shown in brown and located in the hippocampus. Treatment with 1.0 and 2.0 g/kg/day YCTMT reduced the amyloid-accumulated area, showing as decreased size of 4G8-positive area in hippocampus (Figures 4(d) and 4(e)). Quantitative analysis showed that YCTMT treatment reduced Aβ plaque area in hippocampus in a concentration-dependent manner (Figure 4(f)). This result suggests that the beneficial effect of YCTMT on Aβ1−40-induced impairment in cognition might be mediated by reducing Aβ accumulation in the hippocampus.

Figure 4: YCTMT posttreatment decreased Aβ1−40-induced amyloid accumulation. (a) Control. (b) Aβ1−40 infusion (25 pmol). (c)–(e) YCTMT treatment with doses of 0.5, 1.0, and 2.0 g/kg/day. (f) Quantification of amyloid accumulation area. *Represents significant difference between the indicated and normal control group; #between the indicated and Aβ1−40 group, 𝑃 < 0 . 0 5 . The scale bar represents 100 μm.
3.4. YCTMT Significantly Reversed Aβ1−40-Induced Decrement of Ach Area

Ach is an important neurotransmitter and plays critical roles in the formation of learning/memory and etiology of Alzheimer’s disease [47]. To explore the possible mechanism of YCTMT-mediated beneficial role in relieving AD-like symptom, we further evaluated Ach expression using immunohistochemical analysis (Figure 5) and Western Blot (Figure 6). Injection of Aβ1−40 significantly decreased Ach expression in hippocampus compared with the control group (Figures 5(a) and 5(b)). Quantitative data showed that YCTMT reversed Ach area in a concentration-dependent manner in the whole brain. Treatment with 1.0 and 2.0 g/kg/day YCTMT significantly reversed the expression of Ach in the brain (Figures 5(d) and 5(e)). YCTMT-induced reversal of Ach expression level after Aβ1−40 injection was also confirmed with Western Blot. Quantitative result of Western Blot showed that medium- and high-dose YCTMT treatment rescued reduced Ach expression (Figure 6(c)), suggesting the beneficial effect of YCTMT on AD-like symptom. This result suggested that posttreatment with YCTMT could reverse Aβ1−40-reduced diminish of Ach expression correlated with functional deficit in the AD brain.

Figure 5: YCTMT posttreatment reversed Aβ1−40-induced decreases of Ach level. (a) Control. (b) Aβ1−40 infusion (25 pmol). (c)–(e) YCTMT treatment with doses of 0.5, 1.0, and 2.0 g/kg/day, respectively. (f) Quantification of Ach expression. *Represents significant difference between the indicated and normal control group; #between the indicated and Aβ1−40 group, 𝑃 < 0 . 0 5 . The scale bar represents 100 μm.
Figure 6: YCTMT posttreatment reversed Aβ1−40 and Ach protein level. (a) Comparison of protein level of beta-amyloid and Ach using Western Blot. (b) Quantification of amyloid protein level. (c) Quantification of Ach protein level. *represents significant difference between the indicated and normal control group; #between the indicated and Aβ1−40 group, 𝑃 < 0 . 0 5 .

We also found that there was a correlation between amyloid plaque area and acetylcholine expression site ( R = 0 . 7 1 9 ) .

4. Discussion

In this study, we observed a beneficial effect of YCTMT posttreatment on Aβ1−40-induced AD-like symptoms. YCTMT treatment decreased Aβ1−40-induced amyloid burden and reversed declined Ach level in hippocampus. It also improved learning and memory function in treated rats in a dose-dependent manner. These results provide evidence of the therapeutic effect of YCTMT on AD and suggest a potential treatment strategy.

Investigators have established that toxic Aβ is the major player in neuronal damage and dementia in both in vitro culture assays and in the intact brain of animal [48]. Notably, i.c.v. injections of Aβ1−40 into rats produced learning disability, brain morphological changes, and cholinergic neuronal degeneration [49]. In addition, Aβ1−40 induces spatial learning and spatial working memory deficits in animal model [50]. In the present study, we confirmed that continuous infusion of Aβ1−40 into the cerebral ventricle induced deficits in memory retention, spatial learning memory, probe memory, and working memory in the rats. Moreover, posttreatment with YCTMT reversed various types of learning and memory loss caused by Aβ1−40. These results indicated that YCTMT might have beneficial anti-Alzheimer’s disease effects on Aβ1−40-induced AD animal model.

We also found that i.c.v. administration of Aβ1−40-induced Aβ plague formation was consistent with previous report [15, 1820, 22]. Both WB and immunostaining results showed that posttreatment with YCTMT for 7 days downregulated Aβ burden in the rat brain. Aβ1−40 contributes to the progression of AD and directly impairs cholinergic signaling and Ach release [51]. Activities of choline acetyltransferase and acetylcholinesterase, one for synthesis and the other for hydrolysis of acetylcholine, decrease significantly and correlate with the extent of intellectual impairment in Alzheimer’s dementia patients [52]. Coincidently, we also found that posttreatment with YCTMT recovered the expressions of Ach in the rat brains that were challenged with Aβ1−40. These results implied that YCTMT might reduce the production of Aβ plaque, possibly through increasing the expression of Ach. However, the mechanisms underlying the influence of Ach expression need further study.

Traditional Chinese Medicine (TCM) has been around for thousands of years and extensively used in the prevention, diagnosis, and treatment of diseases in China. There are several TCMs that have been used to enhance cognitive function and senile dementia [53]. YCTMT is one of the TCMs and has been conventionally used in the improvement of visual acuity and hearing in purpose. Our results provided new evidence of the beneficial role of YCTMT in AD-associated learning and memory deficits. Oral administration of YCTMT in S.D. rats appeared to reverse the Aβ1−40-impaired memory, spatial learning memory, probe memory, and working memory deficits. YCTMT might inhibit Aβ plague accumulation and reverse Ach decline. This study suggests a potential use of YCTMT as a potential therapeutic agent for treating AD.

5. Conclusion

We have shown that YCTMT inhibits Aβ plague accumulation and rescues reduced acetylcholine expression. This study has provided evidence on the beneficial role of YCTMT in ameliorating amyloid-induced AD-like symptom, indicating that YCTMT may offer an alternative strategy for treating AD.


This study was supported by the Show Chwan Memorial Hospital, Changhua, Taiwan (Grants RD96007 and RD97022).


  1. G. Stuchbury and G. Münch, “Alzheimer's associated inflammation, potential drug targets and future therapies,” Journal of Neural Transmission, vol. 112, no. 3, pp. 429–453, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. R. S. Shah, H. G. Lee, Z. Xiongwei, G. Perry, M. A. Smith, and R. J. Castellani, “Current approaches in the treatment of Alzheimer's disease,” Biomedicine and Pharmacotherapy, vol. 62, no. 4, pp. 199–207, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. D. Hirtz, D. J. Thurman, K. Gwinn-Hardy, M. Mohamed, A. R. Chaudhuri, and R. Zalutsky, “How common are the “common” neurologic disorders?” Neurology, vol. 68, no. 5, pp. 326–337, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Mura, J. F. Dartigues, and C. Berr, “How many dementia cases in France and Europe? Alternative projections and scenarios 2010–2050,” European Journal of Neurology, vol. 17, no. 2, pp. 252–259, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. H. W. Querfurth and F. M. LaFerla, “Alzheimer's disease,” The New England Journal of Medicine, vol. 362, no. 4, pp. 329–344, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Münch, R. Schinzel, C. Loske et al., “Alzheimer's disease—synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts,” Journal of Neural Transmission, vol. 105, no. 4-5, pp. 439–461, 1998. View at Publisher · View at Google Scholar · View at Scopus
  7. W. Retz, W. Gsell, G. Münch, M. Rösler, and P. Riederer, “Free radicals in Alzheimer's disease,” Journal of Neural Transmission, Supplement, vol. 54, pp. 221–236, 1998. View at Scopus
  8. H. W. Klafki, M. Staufenbiel, J. Kornhuber, and J. Wiltfang, “Therapeutic approaches to Alzheimer's disease,” Brain, vol. 129, no. 11, pp. 2840–2855, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. G. Habicht, C. Haupt, R. P. Friedrich et al., “Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Aβ protofibrils,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 49, pp. 19232–19237, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Rönicke, A. Klemm, J. Meinhardt, U. H. Schröder, M. Fändrich, and K. G. Reymann, “Aβ mediated diminution of MTT reduction—an artefact of single cell culture?” PLoS ONE, vol. 3, no. 9, Article ID e3236, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Eckert, S. Hauptmann, I. Scherping et al., “Oligomeric and fibrillar species of β-amyloid (Aβ42) both impair mitochondrial function in P301L tau transgenic mice,” Journal of Molecular Medicine, vol. 86, no. 11, pp. 1255–1267, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. H. C. Huang and Z. F. Jiang, “Accumulated amyloid-β peptide and hyperphosphorylated tau protein: relationship and links in Alzheimer's disease,” Journal of Alzheimer's Disease, vol. 16, no. 1, pp. 15–27, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Sánchez-Alavez, R. A. Gallegos, M. A. Kalafut, D. Games, S. J. Henriksen, and J. R. Criado, “Loss of medial septal modulation of dentate gyrus physiology in young mice overexpressing human β-amyloid precursor protein,” Neuroscience Letters, vol. 330, no. 1, pp. 45–48, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. S. S. Sisodia and P. H. St George-Hyslop, “γ-secretase, Notch, Aβ and Alzheimer's disease: where do the presenilins fit in?” Nature Reviews Neuroscience, vol. 3, no. 4, pp. 281–290, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. E. Tamagno, M. Guglielmotto, M. Aragno et al., “Oxidative stress activates a positive feedback between the γ- and β-secretase cleavages of the β-amyloid precursor protein,” Journal of Neurochemistry, vol. 104, no. 3, pp. 683–695, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Niwa, G. A. Carlson, and C. Iadecola, “Exogenous Aβ1-40 reproduces cerebrovascular alterations resulting from amyloid precursor protein overexpression in mice,” Journal of Cerebral Blood Flow and Metabolism, vol. 20, no. 12, pp. 1659–1668, 2000. View at Scopus
  17. G. Cantarella, D. Uberti, T. Carsana, G. Lombardo, R. Bernardini, and M. Memo, “Neutralization of TRAIL death pathway protects human neuronal cell line from β-amyloid toxicity,” Cell Death and Differentiation, vol. 10, no. 1, pp. 134–141, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. R. Medeiros, R. D. S. Prediger, G. F. Passos et al., “Connecting TNF-α signaling pathways to iNOS expression in a mouse model of Alzheimer's disease: relevance for the behavioral and synaptic deficits induced by amyloid β protein,” Journal of Neuroscience, vol. 27, no. 20, pp. 5394–5404, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. R. D. S. Prediger, R. Medeiros, P. Pandolfo et al., “Genetic deletion or antagonism of kinin B1 and B2 receptors improves cognitive deficits in a mouse model of Alzheimer's disease,” Neuroscience, vol. 151, no. 3, pp. 631–643, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. D. A. Butterfield and C. M. Lauderback, “Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid β-peptide-associated free radical oxidative stress,” Free Radical Biology and Medicine, vol. 32, no. 11, pp. 1050–1060, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. T. Nabeshima, “Protectiye effects of idebenone and α-tocopherol on β-amyloid-(1–42)-induced learning and memory deficits in rats: implication of oxidative stress in β-amyloid-induced neurotoxicity in vivo,” European Journal of Neuroscience, vol. 11, no. 1, pp. 83–90, 1999. View at Scopus
  22. M. Sano, C. Ernesto, R. G. Thomas et al., “A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease,” The New England Journal of Medicine, vol. 336, no. 17, pp. 1216–1222, 1997. View at Publisher · View at Google Scholar · View at Scopus
  23. X. Shi, X. Lu, L. Zhan et al., “Rat hippocampal proteomic alterations following intrahippocampal injection of amyloid beta peptide (1–40),” Neuroscience Letters, vol. 500, no. 2, pp. 87–91, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. Q. Gu, “Contribution of acetylcholine to visual cortex plasticity,” Neurobiology of Learning and Memory, vol. 80, no. 3, pp. 291–301, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Sarter, M. E. Hasselmo, J. P. Bruno, and B. Givens, “Unraveling the attentional functions of cortical cholinergic inputs: interactions between signal-driven and cognitive modulation of signal detection,” Brain Research Reviews, vol. 48, no. 1, pp. 98–111, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. R. T. Bartus, R. L. Dean, B. Beer, and A. S. Lippa, “The cholinergic hypothesis of geriatric memory dysfunction,” Science, vol. 217, no. 4558, pp. 408–417, 1982. View at Scopus
  27. R. Jazi, R. Lalonde, S. Qian, and C. Strazielle, “Regional brain evaluation of acetylcholinesterase activity in PS1/A246E transgenic mice,” Neuroscience Research, vol. 63, no. 2, pp. 106–114, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. J. B. Melo, P. Agostinho, and C. R. Oliveira, “Involvement of oxidative stress in the enhancement of acetylcholinesterase activity induced by amyloid beta-peptide,” Neuroscience Research, vol. 45, no. 1, pp. 117–127, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. F. A. Ling, D. Z. Hui, and S. M. Ji, “Protective effect of recombinant human somatotropin on amyloid β-peptide induced learning and memory deficits in mice,” Growth Hormone and IGF Research, vol. 17, no. 4, pp. 336–341, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. N. Toda, T. Kaneko, and H. Kogen, “Development of an efficient therapeutic agent for alzheimer's disease: design and synthesis of dual inhibitors of acetylcholinesterase and serotonin transporter,” Chemical and Pharmaceutical Bulletin, vol. 58, no. 3, pp. 273–287, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. K. Imahori, “The biochemical study on the etiology of Alzheimer's disease,” Proceedings of the Japan Academy B, vol. 86, pp. 54–61, 2010.
  32. B. R. Ott and N. J. Owens, “Complementary and alternative medicines for Alzheimer's disease,” Journal of Geriatric Psychiatry and Neurology, vol. 11, no. 4, pp. 163–173, 1998. View at Scopus
  33. M. T. Hsieh, W. H. Peng, C. R. Wu, K. Y. Ng, C. L. Cheng, and H. X. Xu, “Review on experimental research of herbal medicines with anti-amnesic activity,” Planta Medica, vol. 76, no. 3, pp. 203–217, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. G. Zhang, A. Liu, Y. Zhou, X. San, T. Jin, and Y. Jin, “Panax ginseng ginsenoside-Rg2 protects memory impairment via anti-apoptosis in a rat model with vascular dementia,” Journal of Ethnopharmacology, vol. 115, no. 3, pp. 441–448, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. J. T. Zhang, “Nootropic mechanisms of ginsenoside Rg1 influence on neuronal plasticity and neurogenesis,” Yaoxue Xuebao, vol. 40, no. 5, pp. 385–388, 2005. View at Scopus
  36. C. Tohda, N. Matsumoto, K. Zou, M. R. Meselhy, and K. Komatsu, “Axonal and dendritic extension by protopanaxadiol-type saponins from Ginseng drugs in SK-N-SH cells,” Japanese Journal of Pharmacology, vol. 90, no. 3, pp. 254–262, 2002. View at Publisher · View at Google Scholar · View at Scopus
  37. C. Tohda, T. Tamura, S. Matsuyama, and K. Komatsu, “Promotion of axonal maturation and prevention of memory loss in mice by extracts of Astragalus mongholicus,” British Journal of Pharmacology, vol. 149, no. 5, pp. 532–541, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Ahn, M. Um, W. Choi, S. Kim, and T. Ha, “Protective effects of Glycyrrhiza uralensis Fisch. on the cognitive deficits caused by β-amyloid peptide 25–35 in young mice,” Biogerontology, vol. 7, no. 4, pp. 239–247, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. Y. Wu and H. Y. Wan, “Protective effect of puerarin on anoxia-reoxygenation induced cerebral cell injury in culture,” Chinese Pharmacological Bulletin, vol. 22, no. 9, pp. 1130–1133, 2006. View at Scopus
  40. F. S. Tsai, H. Y. Cheng, M. T. Hsieh, C. R. Wu, Y. C. Lin, and W. H. Peng, “The ameliorating effects of luteolin on beta-amyloid-induced impairment of water maze performance and passive avoidance in rats,” American Journal of Chinese Medicine, vol. 38, no. 2, pp. 279–291, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. G. Paxinos and C. Watson, The Rat Brain in Stereotaxic Coordinates, Elsevier, San Diego, Calif, USA, 2006.
  42. E. Suits and R. L. Isaacson, “The effects of scopolamine hydrobromide on one-way and two-way avoidance learning in rats,” Neuropharmacology, vol. 7, no. 5, pp. 441–446, 1968. View at Scopus
  43. R. Morris, “Developments of a water-maze procedure for studying spatial learning in the rat,” Journal of Neuroscience Methods, vol. 11, no. 1, pp. 47–60, 1984. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Parle and N. Singh, “Animal models for testing memory,” Asia Pacific Journal of Pharmacology, vol. 16, no. 2, pp. 101–120, 2004. View at Scopus
  45. G. P. Lim, F. Yang, T. Chu et al., “Ibuprofen suppresses plaque pathology and inflammation in a mouse model for alzheimer's disease,” Journal of Neuroscience, vol. 20, no. 15, pp. 5709–5714, 2000. View at Scopus
  46. J. W. Liao, C. K. Hsu, M. F. Wang, W. M. Hsu, and Y. C. Chan, “Beneficial effect of Toona sinensis Roemor on improving cognitive performance and brain degeneration in senescence-accelerated mice,” British Journal of Nutrition, vol. 96, no. 2, pp. 400–407, 2006. View at Publisher · View at Google Scholar · View at Scopus
  47. H. R. Parri and K. T. Dineley, “Nicotinic acetylcholine receptor interaction with β-amyloid: molecular, cellular, and physiological consequences,” Current Alzheimer Research, vol. 7, no. 1, pp. 27–39, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. C. Haass and D. J. Selkoe, “Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide,” Nature Reviews Molecular Cell Biology, vol. 8, no. 2, pp. 101–112, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. A. Nitta, T. Fukuta, T. Hasegawa, and T. Nabeshima, “Continuous infusion of β-amyloid protein into the rat cerebral ventricle induces learning impairment and neuronal and morphological degeneration,” Japanese Journal of Pharmacology, vol. 73, no. 1, pp. 51–57, 1997. View at Scopus
  50. Y. Peng, C. Xing, S. Xu et al., “l-3-n-butylphthalide improves cognitive impairment induced by intracerebroventricular infusion of amyloid-β peptide in rats,” European Journal of Pharmacology, vol. 621, no. 1–3, pp. 38–45, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. S. Kar, A. M. Issa, D. Seto, D. S. Auld, B. Collier, and R. Quirion, “Amyloid β-peptide inhibits high-affinity choline uptake and acetylcholine release in rat hippocampal slices,” Journal of Neurochemistry, vol. 70, no. 5, pp. 2179–2187, 1998. View at Scopus
  52. E. K. Perry, B. E. Tomlinson, G. Blessed, et al., “Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia,” British Medical Journal, vol. 2, no. 6150, pp. 1457–1459, 1978. View at Scopus
  53. H. Yan, L. Li, and X. C. Tang, “Treating senile dementia with traditional Chinese medicine,” Clinical Interventions in Aging, vol. 2, no. 2, pp. 201–208, 2007. View at Scopus